Determination of serum M30 and M65 levels and its clinical significance in patients with HBV-related acute-on-chronic liver failure

• Main Author: ZHU Bing
• Format: Article
• Language: zho
• Published: Editorial Department of Journal of Clinical Hepatology 2013-09-01
• Series: Linchuang Gandanbing Zazhi
• Subjects: liver failure; hepatitis B; chronic; keratin-18
• Online Access: http://www.lcgdbzz.org/qk_content.asp?id=5466&ClassID=8695518

ObjectiveTo determine the serum M30 and M65 levels in patients with HBV-related acute-on-chronic liver failure (ACLF) and to investigate their association with this disease. MethodsThirty-one patients with HBV-related ACLF (20 cases with response to treatment and 11 cases without response to treatment), 20 patients with chronic hepatitis B (CHB), and 10 healthy controls were enrolled in the study. Serum M65 and M30 levels were measured by enzyme-linked immunosorbent assay. Analysis of variance was used for comparison among groups; q-test was used for pairwise comparison. ResultsThe serum M30 and M65 levels of ACLF patients (508.65±340.16 and 768.75±290.02 U/L) were significantly higher than those of CHB patients (212.27±91.33 and 384.40±134.46 U/L) and healthy controls (94.12±17.64 and 121.99±29.25 U/L) (P＜0.05 for all comparisons). In the ACLF patients, the serum level of M30 was positively correlated with that of M65 (r=0.78, P＜0.05); no significant differences were seen between the cases with response to treatment and those without response to treatment in serum M30 and M65 levels (572.38±349.45 vs 436.14±285.59 U/L, P=0.29; 81725±307.66 vs 703.90±221.37 U/L, P=0.31). ConclusionSerum levels of M30 and M65 are sensitive indicators for the necrosis and apoptosis of hepatocytes. Significant increases in serum M30 and M65 levels are observed in patients with HBV-related ACLF.